A Systematic Review on the Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in Gastrointestinal Motility Disorders: More Control, Less Risk

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Sep 9

PMID 36081982

Authors

Maitri V Acharekar

Sara E Guerrero Saldivia

Sumedha Unnikrishnan

Yeny Y Chavarria

Adebisi O Akindele

Ana P Jalkh

Aziza K Eastmond

Chaitra Shetty

Syed Muhammad Hannan A Rizvi

Joudi Sharaf

Kerry-Ann D Williams

Maha Tariq

Prachi Balani

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal motility disorders have been thought to occur due to an imbalance in the interaction of the gut-brain axis, which is regulated by serotonin. This recent discovery can be exploited to find newer therapeutic agents such as selective serotonin reuptake inhibitors for functional gastrointestinal disorders. PubMed, PubMed Central (PMC), and Medline databases were used to obtain the data. Meta-analyses, systematic reviews, randomized control trials, and reviews were included and analyzed in the data. Of the 19240 studies, 23 were extracted, and after appropriate quality assessment, they were utilized in this systematic review. They included two meta-analyses, four systematic reviews, two randomized control trials, and 15 review articles. The systematic review focuses on the efficacy of selective serotonin reuptake inhibitors (SSRIs) as compared to other treatment modalities for disorders of gut-brain interaction. It explores various studies analyzing SSRIs for their mechanism of action, their desirable effects for treating irritable bowel syndrome, and their tolerability in patients. SSRIs are effective and safe in treating overall symptoms of gastrointestinal motility disorders, particularly constipation-predominant disorders. They seem to have a better side effect profile than other drugs. This should encourage physicians to prescribe SSRIs early on in the disease.

Citing Articles

Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies.

El Baassiri M, Raouf Z, Badin S, Escobosa A, Sodhi C, Nasr I J Neuroinflammation. 2024; 21(1):124.

PMID: 38730498 PMC: 11083845. DOI: 10.1186/s12974-024-03118-3.

References

Mawe G, Hoffman J . Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013; 10(8):473-86. PMC: 4048923. DOI: 10.1038/nrgastro.2013.105. View

Tornblom H, Drossman D . Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Curr Gastroenterol Rep. 2018; 20(12):58. PMC: 6223713. DOI: 10.1007/s11894-018-0664-3. View

Guzel T, Mirowska-Guzel D . The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy. Molecules. 2022; 27(5). PMC: 8911970. DOI: 10.3390/molecules27051680. View

Qin D, Yue L, Xue B, Chen M, Tang T, Zheng H . Pharmacological treatments for patients with irritable bowel syndrome: An umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore). 2019; 98(32):e15920. PMC: 6709044. DOI: 10.1097/MD.0000000000015920. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Wall G, Bryant G, Bottenberg M, Maki E, Miesner A . Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014; 20(27):8796-806. PMC: 4112883. DOI: 10.3748/wjg.v20.i27.8796. View

Black C, Yuan Y, Selinger C, Camilleri M, Quigley E, Moayyedi P . Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019; 5(2):117-131. DOI: 10.1016/S2468-1253(19)30324-3. View

Ghaffari P, Shoaie S, Nielsen L . Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. J Transl Med. 2022; 20(1):173. PMC: 9004034. DOI: 10.1186/s12967-022-03365-z. View

Grad S, Dumitrascu D . Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions. Dig Dis. 2019; 38(2):122-127. DOI: 10.1159/000505287. View

10.

Mishima Y, Ishihara S . Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome. Int J Mol Sci. 2021; 22(19). PMC: 8508930. DOI: 10.3390/ijms221910235. View

11.

Adriani A, Ribaldone D, Astegiano M, Durazzo M, Saracco G, Pellicano R . Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018; 60(4):213-222. DOI: 10.23736/S0031-0808.18.03541-3. View

12.

Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V . Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018; 162(1):1-9. DOI: 10.5507/bp.2017.057. View

13.

Bellini M, Gambaccini D, Stasi C, Urbano M, Marchi S, Usai-Satta P . Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014; 20(27):8807-20. PMC: 4112881. DOI: 10.3748/wjg.v20.i27.8807. View

14.

Talley N, Locke G, Saito Y, Almazar A, Bouras E, Howden C . Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015; 149(2):340-9.e2. PMC: 4516571. DOI: 10.1053/j.gastro.2015.04.020. View

15.

Gewandter J, Chaudari J, Iwan K, Kitt R, As-Sanie S, Bachmann G . Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: An ACTTION Systematic Review. J Pain. 2018; 19(7):717-726. PMC: 6026036. DOI: 10.1016/j.jpain.2018.01.007. View

16.

Kreiter D, Drukker M, Mujagic Z, Vork L, Rutten B, van Os J . Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. J Psychosom Res. 2021; 141:110351. DOI: 10.1016/j.jpsychores.2020.110351. View

17.

Moser G, Fournier C, Peter J . Intestinal microbiome-gut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2017; 168(3-4):62-66. PMC: 5860136. DOI: 10.1007/s10354-017-0592-0. View

18.

Mittal R, Debs L, Patel A, Nguyen D, Patel K, OConnor G . Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell Physiol. 2016; 232(9):2359-2372. PMC: 5772764. DOI: 10.1002/jcp.25518. View

19.

Scaciota A, Matos D, Rosa M, Colovati M, Bellotto E, Martimbianco A . INTERVENTIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW OF COCHRANE SYSTEMATIC REVIEWS. Arq Gastroenterol. 2021; 58(1):120-126. DOI: 10.1590/S0004-2803.202100000-20. View

20.

Aziz M, Kumar J, Muhammad Nawawi K, Ali R, Mokhtar N . Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain. Nutrients. 2021; 13(9). PMC: 8468817. DOI: 10.3390/nu13093061. View